The first and only treatment to show superior efficacy vs standard single-agent chemotherapy in FRα-positive* PROC1-3
*FRα positive is defined as ≥75% of viable tumor cells with moderate (2+) and/or strong (3+) membrane staining based on an IHC assay.4
FRα=folate receptor alpha; IHC=immunohistochemistry; PROC=platinum-resistant ovarian cancer.
PFS: EFFICACY OF ELAHERE IN SELECT EXPLORATORY SUBGROUP ANALYSES BY TREATMENT HISTORY2
This study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature. No formal inferences can be drawn.2
CI=confidence interval; PARPi=poly(ADP-ribose) polymerase inhibitor; PFS=progression-free survival.
OS: EFFICACY OF ELAHERE IN SELECT EXPLORATORY SUBGROUP ANALYSES BY TREATMENT HISTORY2
This study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature. No formal inferences can be drawn.2
OS=overall survival.
ORR: EFFICACY OF ELAHERE IN SELECT EXPLORATORY SUBGROUP ANALYSES BY TREATMENT HISTORY2
This study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature. No formal inferences can be drawn.2
ORR population includes 2 patients from each arm that do not appear in the Prescribing Information analysis (patients removed had a CR and PD in the ELAHERE arm and an SD and NE in the investigator's choice arm).
CR=complete response; NE=not evaluable; ORR=overall response rate; PD=progressive disease; SD=stable disease.
PFS: RESULTS IN A LONGER-TERM FOLLOW-UP5*
After the primary analysis data cutoff of March 6, 2023, ELAHERE continued to be studied in patients until October 27, 2023, with a median follow-up of 20.3 months. This represents the updated nonanalytical results from the extended data cutoff5
Post hoc PFS by investigator (ITT population)5
*Through day 120 after the primary analysis.5
No inference can be drawn from this data set. Follow-up analysis is exploratory and data are descriptive in nature.
HR=hazard ratio; ITT=intent-to-treat; mPFS=median progression-free survival.
OS: CONSISTENT RESULTS IN A LONGER-TERM FOLLOW-UP5*
After the primary analysis data cutoff of March 6, 2023, ELAHERE continued to be studied in patients until October 27, 2023, with a median follow-up of 20.3 months. This represents the updated nonanalytical results from the extended data cutoff5
Post hoc OS (ITT population)5
*Through day 120 after the primary analysis.5
No inference can be drawn from this data set. Follow-up analysis is exploratory and data are descriptive in nature.
mOS=median overall survival.
Need more information
about FRα testing?
A representative can answer additional questions
you may have about testing for FRα.
Discover more
about dosing
Find comprehensive dosing and administration information,
plus downloadable resources.